Floatz logo

dt2216

Childhood Fibrolamellar Carcinoma

Children's Oncology GroupSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Childhood Fibrolamellar Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Children's Oncology Group
Phase 3BB
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 3BB
Nivolumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Sorafenib
St. Jude Children's Research Hospital
Phase 3B
Eloxatin
Children's Oncology Group
Phase 3B

View all 37 →

Same molecule, other indications

dt2216 is also rated in:

Recurrent Childhood Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
Refractory Childhood Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
Recurrent Malignant Solid NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →